Curocell

At a glance

Curocell filed 47 disclosures in the last 12 months, including 13 insider, 6 5% holder and 2 issuance. The most recent key filing was on Oct 21: Executive's holding rose by 2,000 sh (stock option).

Revenue for 2025 was ₩0. Debt was 2083% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩0 and operating loss of ₩17.5B.

The 2025 annual report lists 146 employees with an average tenure of 2.6 years and average pay of ₩54.5M, #1243 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩140.6M each on average. It paid no cash dividend for 2025. 김건수 and related parties held 18.69% at year end.

From the 2025 annual report

Staff: 146 (65 men, 81 women), of whom 5 on fixed-term contracts. Total pay for the year: ₩8B. Directors and auditors: 6, paid ₩843.8M in total.

No cash dividend was paid for 2025.

Largest shareholder

김건수 holds 10.67%; with 8 related parties the group holds 18.69% of common shares at year end (from 18.52% at the start of the year).

Source: 2025 annual business report (DART). How figures are combined

Financial summary